{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:49:19Z","timestamp":1788990559917,"version":"build-2803163510"},"reference-count":132,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer immunoprevention applies immunologic approaches such as vaccines to prevent, rather than to treat or cure, cancer. Despite limited success in the treatment of advanced disease, the development of cancer vaccines to intercept premalignant states is a promising area of current research. These efforts are supported by the rationale that vaccination in the premalignant setting is less susceptible to mechanisms of immune evasion compared with established cancer. Prophylactic vaccines have already been developed for a minority of cancers mediated by oncogenic viruses (e.g., hepatitis B and human papillomavirus). Extending the use of preventive vaccines to non-virally driven malignancies remains an unmet need to address the rising global burden of cancer. This review provides a broad overview of clinical trials in cancer immunoprevention with an emphasis on emerging vaccine targets and delivery platforms, translational challenges, and future directions.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-22-0478","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T23:20:36Z","timestamp":1680304836000},"page":"483-495","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-0566","authenticated-orcid":false,"given":"Saurav D.","family":"Haldar","sequence":"first","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-3761","authenticated-orcid":false,"given":"Eduardo","family":"Vilar","sequence":"additional","affiliation":[{"name":"2Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-9978","authenticated-orcid":false,"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[{"name":"3Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0049","authenticated-orcid":false,"given":"Neeha","family":"Zaidi","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"2025112418293682700_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca Cancer J Clin"},{"key":"2025112418293682700_bib2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"2025112418293682700_bib3","first-page":"103","article-title":"Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention","volume":"7","author":"Vonderheide","year":"2007","journal-title":"Discov Med"},{"key":"2025112418293682700_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev-cancerbio-030617-050558","article-title":"Prophylactic vaccines for nonviral cancers","volume":"2","author":"Scott","year":"2018","journal-title":"Annu Rev Cancer Biol"},{"key":"2025112418293682700_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"2025112418293682700_bib6","doi-asserted-by":"crossref","first-page":"e146956","DOI":"10.1172\/JCI146956","article-title":"Vaccines for immunoprevention of cancer","volume":"131","author":"Enokida","year":"2021","journal-title":"J Clin Invest"},{"key":"2025112418293682700_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(22)00081-X","article-title":"President Biden outlines plans for Cancer Moonshot 2.0","volume":"23","author":"Gourd","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025112418293682700_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1940-6207.CAPR-10-0034","article-title":"Highlighting the science of cancer prevention","volume":"3","author":"Blackburn","year":"2010","journal-title":"Cancer Prev Res"},{"key":"2025112418293682700_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41698-018-0075-9","article-title":"Cancer prevention and screening: the next step in the era of precision medicine","volume":"3","author":"Loomans-Kropp","year":"2019","journal-title":"Npj Precis Oncol"},{"key":"2025112418293682700_bib10","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.23945","article-title":"Primary prevention, aging, and cancer: overview and future perspectives","volume":"113","author":"Miller","year":"2008","journal-title":"Cancer"},{"key":"2025112418293682700_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccm.2019.10.002","article-title":"Primary and secondary prevention of lung cancer tobacco treatment","volume":"41","author":"Kathuria","year":"2020","journal-title":"Clin Chest Med"},{"key":"2025112418293682700_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/heapro\/dah310","article-title":"Primary prevention of skin cancer: a review of sun protection in Australia and internationally","volume":"19","author":"Stanton","year":"2004","journal-title":"Health Promot Int"},{"key":"2025112418293682700_bib13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib14","doi-asserted-by":"crossref","first-page":"djv309","DOI":"10.1093\/jnci\/djv309","article-title":"Cancer prevention: obstacles, challenges, and the road ahead","volume":"108","author":"Meyskens","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2025112418293682700_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/2159-8290.CD-17-1415","article-title":"Precision prevention and early detection of cancer: fundamental principles","volume":"8","author":"Rebbeck","year":"2018","journal-title":"Cancer Discov"},{"key":"2025112418293682700_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ijgo.12187","article-title":"Optimizing secondary prevention of cervical cancer: recent advances and future challenges","volume":"138","author":"Ogilvie","year":"2017","journal-title":"Int J Gynecol Amp Obstetrics"},{"key":"2025112418293682700_bib17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1940-6207.CAPR-11-0195","article-title":"Cancer interception","volume":"4","author":"Blackburn","year":"2011","journal-title":"Cancer Prev Res"},{"key":"2025112418293682700_bib18","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1608077113","article-title":"Leveraging premalignant biology for immune-based cancer prevention","volume":"113","author":"Spira","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025112418293682700_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/a0036513","article-title":"Tertiary prevention in cancer care","volume":"70","author":"Jacobsen","year":"2015","journal-title":"Am Psychol"},{"key":"2025112418293682700_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JOP.18.00617","article-title":"Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO clinical practice guideline focused update","volume":"15","author":"Burstein","year":"2019","journal-title":"J Oncol Pract"},{"key":"2025112418293682700_bib21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine \u2014 demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(84)92740-5","article-title":"Clinical evaluation of a recombinant hepatitis B vaccine","volume":"324","author":"Jilg","year":"1984","journal-title":"Lancet"},{"key":"2025112418293682700_bib23","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in healthy adults 40\u201370 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"2025112418293682700_bib24","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1016\/j.vaccine.2015.05.070","article-title":"Immunogenicity of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18\u201370 years of age","volume":"33","author":"Janssen","year":"2015","journal-title":"Vaccine"},{"key":"2025112418293682700_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J Infect Dis"},{"key":"2025112418293682700_bib26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Group TFIS","year":"2007","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib27","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"2025112418293682700_bib29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomized, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025112418293682700_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib32","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"key":"2025112418293682700_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of hepatitis B immunization of infants in preventing liver cancer","volume":"151","author":"Chang","year":"2016","journal-title":"Gastroenterology"},{"key":"2025112418293682700_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1086\/315259","article-title":"Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program","volume":"181","author":"Harpaz","year":"2000","journal-title":"J Infect Dis"},{"key":"2025112418293682700_bib36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.24442","article-title":"Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program","volume":"54","author":"McMahon","year":"2011","journal-title":"Hepatology"},{"key":"2025112418293682700_bib37","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2468-2667(18)30183-X","article-title":"The projected timeframe until cervical cancer elimination in Australia: a modelling study","volume":"4","author":"Hall","year":"2019","journal-title":"Lancet Public Heal"},{"key":"2025112418293682700_bib38","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S2468-2667(20)30006-2","article-title":"Projected time to elimination of cervical cancer in the USA: a comparative modelling study","volume":"5","author":"Burger","year":"2020","journal-title":"Lancet Public Heal"},{"key":"2025112418293682700_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"key":"2025112418293682700_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gutjnl-2020-322200","article-title":"Mass eradication of helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands","volume":"70","author":"Chiang","year":"2021","journal-title":"Gut"},{"key":"2025112418293682700_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nri.2017.140","article-title":"The dawn of vaccines for cancer prevention","volume":"18","author":"Finn","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025112418293682700_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"2025112418293682700_bib43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"2025112418293682700_bib44","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2022.40.4_suppl.519","article-title":"KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation","volume":"40","author":"Bekaii-Saab","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025112418293682700_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2022.40.4_suppl.591","article-title":"Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor","volume":"40","author":"Gustafson","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025112418293682700_bib49","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1\u2013KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov"},{"key":"2025112418293682700_bib50","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112418293682700_bib51","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1038\/onc.2013.29","article-title":"Evolution and dynamics of pancreatic cancer progression","volume":"32","author":"Yachida","year":"2013","journal-title":"Oncogene"},{"key":"2025112418293682700_bib52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat Rev Gastroentero"},{"key":"2025112418293682700_bib53","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2014.02.055","article-title":"A listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice","volume":"146","author":"Keenan","year":"2014","journal-title":"Gastroenterology"},{"key":"2025112418293682700_bib54","doi-asserted-by":"crossref","first-page":"82689","DOI":"10.18632\/oncotarget.19831","article-title":"Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"key":"2025112418293682700_bib55","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol Med"},{"key":"2025112418293682700_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1309\/9R6673QEC06D86Y4","article-title":"Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various SitesAn immunohistochemical study","volume":"122","author":"Lau","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"2025112418293682700_bib57","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/jsre.1996.0264","article-title":"A phase I trial of a synthetic mucin peptide vaccine induction of specific immune reactivity in patients with adenocarcinoma","volume":"63","author":"Goydos","year":"1996","journal-title":"J Surg Res"},{"key":"2025112418293682700_bib59","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jgm.397","article-title":"Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer","volume":"5","author":"Rochlitz","year":"2003","journal-title":"J Gene Med"},{"key":"2025112418293682700_bib60","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1\u2013pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib61","first-page":"955","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2008","journal-title":"Cancer Ther"},{"key":"2025112418293682700_bib62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10637-008-9187-3","article-title":"MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure","volume":"27","author":"Dreicer","year":"2009","journal-title":"Invest New Drugs"},{"key":"2025112418293682700_bib63","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non\u2013small cell lung cancer: a controlled phase IIB trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025112418293682700_bib64","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non\u2013small cell lung cancer (TIME): results from the phase IIb part of a randomized, double-blind, placebo-controlled, phase IIb\/III trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025112418293682700_bib65","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-2407-12-144","article-title":"LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases\u2013a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial","volume":"12","author":"Schimanski","year":"2012","journal-title":"BMC Cancer"},{"key":"2025112418293682700_bib66","first-page":"463","article-title":"Delivering two tumor antigens survivin and mucin-1 on virus-like particles enhances antitumor immune responses","volume":"9","author":"Campbell","year":"2021","journal-title":"Nato Adv Sci Inst Se"},{"key":"2025112418293682700_bib67","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.3390\/ijms232315130","article-title":"Breast cancer vaccine containing a novel Toll-like receptor 7 agonist and an aluminum adjuvant exerts antitumor effects","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025112418293682700_bib68","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev Res"},{"key":"2025112418293682700_bib69","first-page":"CCR\u201322\u20133168","article-title":"Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma","author":"Schoen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib70","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"2025112418293682700_bib71","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.MP.0000038462.62634.B1","article-title":"The role of HER2\/neu overexpression\/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast","volume":"15","author":"Latta","year":"2002","journal-title":"Modern Pathol"},{"key":"2025112418293682700_bib72","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7150\/jca.2.232","article-title":"Biological markers in DCIS and risk of breast recurrence: a systematic review","volume":"2","author":"Lari","year":"2011","journal-title":"J Cancer"},{"key":"2025112418293682700_bib73","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/0008-5472.CAN-06-4038","article-title":"Targeting HER-2\/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion","volume":"67","author":"Czerniecki","year":"2007","journal-title":"Cancer Res"},{"key":"2025112418293682700_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1479-5876-5-42","article-title":"Long term disease-free survival and T-cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2","volume":"5","author":"Morse","year":"2007","journal-title":"J Transl Med"},{"key":"2025112418293682700_bib75","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","article-title":"Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte\u2013macrophage colony-stimulating factor\u2013secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation","volume":"27","author":"Emens","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025112418293682700_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1479-5876-8-53","article-title":"Vaccination with a plasmid DNA encoding HER-2\/neu together with low doses of GM-CSF and IL2 in patients with metastatic breast carcinoma: a pilot clinical trial","volume":"8","author":"Norell","year":"2010","journal-title":"J Transl Med"},{"key":"2025112418293682700_bib77","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1158\/2326-6066.CIR-14-0058","article-title":"A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF\u2013secreting breast tumor vaccine for HER2+ metastatic breast cancer","volume":"2","author":"Chen","year":"2014","journal-title":"Cancer Immunol"},{"key":"2025112418293682700_bib78","doi-asserted-by":"crossref","first-page":"66192","DOI":"10.18632\/oncotarget.11751","article-title":"Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence","volume":"7","author":"Mittendorf","year":"2016","journal-title":"Oncotarget"},{"key":"2025112418293682700_bib79","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0b013e318235f512","article-title":"A novel dendritic cell\u2013based immunization approach for the induction of durable Th1-polarized anti-HER-2\/neu responses in women with early breast cancer","volume":"35","author":"Koski","year":"2012","journal-title":"J Immunother"},{"key":"2025112418293682700_bib81","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"key":"2025112418293682700_bib82","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","article-title":"Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial","volume":"23","author":"Lowenfeld","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0198-8859(97)00255-3","article-title":"The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors","volume":"59","author":"Kawashima","year":"1998","journal-title":"Hum Immunol"},{"key":"2025112418293682700_bib84","doi-asserted-by":"crossref","first-page":"PD11\u201309\u2013PD11\u201309","DOI":"10.1158\/1538-7445.SABCS20-PD11-09","article-title":"Abstract PD11\u201309: vadis trial: phase II trial of nelipepimut-S peptide vaccine in women with DCIS of the breast","volume":"81","author":"O'Shea","year":"2021","journal-title":"Cancer Res"},{"key":"2025112418293682700_bib85","doi-asserted-by":"crossref","first-page":"e183267","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial","volume":"4","author":"Nooka","year":"2018","journal-title":"Jama Oncol"},{"key":"2025112418293682700_bib86","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2022.40.16_suppl.2004","article-title":"Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma","volume":"40","author":"Reardon","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025112418293682700_bib87","doi-asserted-by":"crossref","first-page":"31344","DOI":"10.18632\/oncotarget.5181","article-title":"The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic","volume":"6","author":"Gabitzsch","year":"2015","journal-title":"Oncotarget"},{"key":"2025112418293682700_bib88","doi-asserted-by":"crossref","first-page":"vi362","DOI":"10.1093\/annonc\/mdw378.10","article-title":"1056PD preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers","volume":"27","author":"Westdorp","year":"2016","journal-title":"Ann Oncol"},{"key":"2025112418293682700_bib89","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-20-1072","article-title":"A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability","volume":"80","author":"Leoni","year":"2020","journal-title":"Cancer Res"},{"key":"2025112418293682700_bib90","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","article-title":"Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade","volume":"10","author":"D'Alise","year":"2019","journal-title":"Nat Commun"},{"key":"2025112418293682700_bib91","doi-asserted-by":"crossref","first-page":"eabo7604","DOI":"10.1126\/scitranslmed.abo7604","article-title":"Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection","volume":"14","author":"D'Alise","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025112418293682700_bib92","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/bloodadvances.2019000300","article-title":"A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis","volume":"3","author":"Manasanch","year":"2019","journal-title":"Blood Adv"},{"key":"2025112418293682700_bib93","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"2025112418293682700_bib94","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.smim.2008.07.001","article-title":"Specificity in cancer immunotherapy","volume":"20","author":"Schietinger","year":"2008","journal-title":"Semin Immunol"},{"key":"2025112418293682700_bib95","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumor-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025112418293682700_bib96","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","article-title":"5T4 oncofoetal antigen: an attractive target for immune intervention in cancer","volume":"66","author":"Stern","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2025112418293682700_bib97","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.185.5.833","article-title":"Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes","volume":"185","author":"Theobald","year":"1997","journal-title":"J Exp Medicine"},{"key":"2025112418293682700_bib98","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.4161\/21645515.2014.973314","article-title":"To affinity and beyond: harnessing the T-cell receptor for cancer immunotherapy","volume":"10","author":"Thaxton","year":"2014","journal-title":"Hum Vacc Immunother"},{"key":"2025112418293682700_bib99","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"2025112418293682700_bib100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1084\/jem.20172188","article-title":"Shared cancer neoantigens: making private matters public","volume":"215","author":"Klebanoff","year":"2018","journal-title":"J Exp Med"},{"key":"2025112418293682700_bib101","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat Cancer"},{"key":"2025112418293682700_bib102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"2025112418293682700_bib103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112418293682700_bib104","doi-asserted-by":"crossref","first-page":"e136991","DOI":"10.1172\/jci.insight.136991","article-title":"Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development","volume":"5","author":"Zaidi","year":"2020","journal-title":"JCI Insight"},{"key":"2025112418293682700_bib105","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"2025112418293682700_bib106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The changing landscape of therapeutic cancer vaccines\u2014novel platforms and neoantigen identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025112418293682700_bib108","doi-asserted-by":"crossref","first-page":"e156211","DOI":"10.1172\/JCI156211","article-title":"Messenger RNA vaccines for cancer immunotherapy: progress promotes promise","volume":"132","author":"Huff","year":"2022","journal-title":"J Clin Invest"},{"key":"2025112418293682700_bib109","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2025112418293682700_bib110","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"2025112418293682700_bib111","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20031787","article-title":"Premalignant lesions as targets for cancer vaccines","volume":"198","author":"Finn","year":"2003","journal-title":"J Exp Medicine"},{"key":"2025112418293682700_bib112","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium, and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"2025112418293682700_bib113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"2025112418293682700_bib114","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"2025112418293682700_bib115","doi-asserted-by":"crossref","first-page":"869990","DOI":"10.3389\/fimmu.2022.869990","article-title":"Long-lasting T-cell responses in BNT162b2 COVID-19 mRNA vaccinees and COVID-19 convalescent patients","volume":"13","author":"Hurme","year":"2022","journal-title":"Front Immunol"},{"key":"2025112418293682700_bib116","first-page":"644","article-title":"Multifunctional immunoadjuvants for use in minimalist nucleic acid vaccines","volume":"13","author":"Abbasi","year":"2021","journal-title":"Pharm"},{"key":"2025112418293682700_bib117","doi-asserted-by":"crossref","first-page":"21782","DOI":"10.1039\/C9NR05475H","article-title":"Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant","volume":"11","author":"Yang","year":"2019","journal-title":"Nanoscale"},{"key":"2025112418293682700_bib118","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/sj.gt.3302874","article-title":"Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells","volume":"14","author":"Bontkes","year":"2007","journal-title":"Gene Ther"},{"key":"2025112418293682700_bib119","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1349-7006.2007.00698.x","article-title":"Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte\u2013macrophage colony-stimulating factor RNA","volume":"99","author":"Naka","year":"2008","journal-title":"Cancer Sci"},{"key":"2025112418293682700_bib120","doi-asserted-by":"crossref","first-page":"44123","DOI":"10.18632\/oncotarget.6536","article-title":"Transpresentation of interleukin-15 by IL15\/IL15R\u03b1 mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity","volume":"6","author":"Van den Bergh","year":"2015","journal-title":"Oncotarget"},{"key":"2025112418293682700_bib121","doi-asserted-by":"crossref","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025112418293682700_bib122","volume-title":"Moderna and Merck Announce mRNA-4157\/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA (pembrolizumab), Met Primary Efficacy Endpoint in phase IIb KEYNOTE-942 Trial [Internet]"},{"key":"2025112418293682700_bib123","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of responses to immune checkpoint blockade in advanced melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat Commun"},{"key":"2025112418293682700_bib124","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti\u2013PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"key":"2025112418293682700_bib125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2025112418293682700_bib126","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib127","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00262-016-1838-1","article-title":"Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas","volume":"65","author":"Beatty","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2025112418293682700_bib128","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1078-0432.CCR-21-2585","article-title":"Diminished immune surveillance during histologic progression of intraductal papillary mucinous neoplasms offers a therapeutic opportunity for cancer interception","volume":"28","author":"Hernandez","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112418293682700_bib129","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","article-title":"Immune escape in breast cancer during in situ to invasive carcinoma transition","volume":"7","author":"Gil Del Alcazar","year":"2017","journal-title":"Cancer Discov"},{"key":"2025112418293682700_bib130","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/cam4.3833","article-title":"The immune landscape during the tumorigenesis of cervical cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Med-us"},{"key":"2025112418293682700_bib131","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3389\/fimmu.2019.02385","article-title":"Moving immunoprevention beyond virally mediated malignancies: do we need to link it to early detection?","volume":"10","author":"Dhodapkar","year":"2019","journal-title":"Front Immunol"},{"key":"2025112418293682700_bib132","doi-asserted-by":"crossref","first-page":"IA001","DOI":"10.1158\/1940-6215.TACPAD22-IA001","article-title":"Abstract IA001: Intercepting pancreatic cancer development with oncogene targeted immunotherapy","volume":"15","author":"Jaffee","year":"2022","journal-title":"Cancer Prev Res"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/doi\/10.1158\/1940-6207.CAPR-22-0478\/3318443\/capr-22-0478.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/doi\/10.1158\/1940-6207.CAPR-22-0478\/3324135\/capr-22-0478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/16\/9\/483\/3356595\/483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/16\/9\/483\/3356595\/483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:30:05Z","timestamp":1764027005000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/16\/9\/483\/728464\/Worth-a-Pound-of-Cure-Emerging-Strategies-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":132,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,3,31]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-22-0478","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}